Publications by authors named "Gu Helen"

Claim this Profile
P
Pharmacogenomic, pharmacokinetic, and safety analysis of CYP3A4/CYP3A5 polymorphisms of midostaurin in patients with acute myeloid leukemia.
Romain Sechaud, Thomas Peters, Helen Gu, Gholamreza Rahmanzadeh, Gopal Krishna Sharma

Eur J Clin Pharmacol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of various experimental conditions and mechanistic static versus dynamic models to predict time-dependent CYP3A4/5 inhibition potential of drugs.
Badée Justine, Gu Helen, Huth Felix, Poller Birk, Schiller Hilmar

Drug Metab Dispos· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physiologically based pharmacokinetic modelling to predict artemether and lumefantrine exposure in neonates weighing less than 5 kg treated with artemether-lumefantrine to supplement the clinical data from the CALINA study.
Helen Gu, Nada Abla, Vinay Kumar Venishetty, Birgit Schoeberl, Julia Zack

Trop Med Health· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physiologically based pharmacokinetic modeling of midostaurin and metabolites at steady-state to bridge drug interaction scenarios in lieu of clinical trials.
Helen Gu, Romain Sechaud, Imad Hanna, Ryan Pelis, Heidi J Einolf

Drug Metab Dispos· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of midostaurin on the pharmacokinetics of P-gp, BCRP, and CYP2D6 substrates: assessing potential drug-drug interactions in healthy participants : Brief title: Drug-drug interaction of midostaurin.
Romain Sechaud, Helen Gu, Gholamreza Rahmanzadeh, Ovidiu Chiparus, Astrid Breitschaft

Cancer Chemother Pharmacol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Midostaurin drug interaction profile: a comprehensive assessment of CYP3A, CYP2B6, and CYP2C8 drug substrates, and oral contraceptives in healthy participants.
Romain Sechaud, Helen Gu, Gholamreza Rahmanzadeh, Amanda Taylor, Ovidiu Chiparus

Cancer Chemother Pharmacol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Midostaurin drug interaction profile: a comprehensive assessment of CYP3A, CYP2B6, and CYP2C8 drug substrates, and oral contraceptives in healthy participants.
Romain Sechaud, Helen Gu, Gholamreza Rahmanzadeh, Amanda Taylor, Ovidiu Chiparus

Cancer Chemother Pharmacol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the Absorption, Metabolism, and Excretion of a Single Oral 1-mg Dose of Tropifexor in Healthy Male Subjects and the Concentration Dependence of Tropifexor Metabolism.
Lydia Wang-Lakshman, Zhuang Miao, Lai Wang, Helen Gu, Mark Kagan

Drug Metab Dispos· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Simultaneous Physiologically Based Pharmacokinetic (PBPK) Modeling of Parent and Active Metabolites to Investigate Complex CYP3A4 Drug-Drug Interaction Potential: A Case Example of Midostaurin.
Helen Gu, Catherine Dutreix, Sam Rebello, Taoufik Ouatas, Lai Wang

Drug Metab Dispos· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Clinical Drug Interaction Potential of Clofazimine Using Static and Dynamic Modeling Approaches.
Ramachandra Sangana, Helen Gu, Dung Yu Chun, Heidi J Einolf

Drug Metab Dispos· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physiologically Based Pharmacokinetic Model Predictions of Panobinostat (LBH589) as a Victim and Perpetrator of Drug-Drug Interactions.
Heidi J Einolf, Wen Lin, Christina S Won, Lai Wang, Helen Gu

Drug Metab Dispos· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estimation of fractions metabolized by hepatic CYP enzymes using a concept of inter-system extrapolation factors (ISEFs) - a comparison with the chemical inhibition method.
Ken-Ichi Umehara, Felix Huth, Helen Gu, Hilmar Schiller, Tycho Heimbach

Drug Metab Pers Ther· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical disposition, metabolism and in vitro drug-drug interaction properties of omadacycline.
Jimmy Flarakos, Yancy Du, Helen Gu, Lai Wang, Heidi J Einolf

Xenobiotica· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug Interaction Potential of Osilodrostat (LCI699) Based on Its Effect on the Pharmacokinetics of Probe Drugs of Cytochrome P450 Enzymes in Healthy Adults.
Sara Armani, Lillian Ting, Nicholas Sauter, Christelle Darstein, Anadya Prakash Tripathi, Helen Gu

Clin Drug Investig· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Midostaurin, a Novel Protein Kinase Inhibitor for the Treatment of Acute Myelogenous Leukemia: Insights from Human Absorption, Metabolism, and Excretion Studies of a BDDCS II Drug.
Handan He, Phi Tran, Helen Gu, Vivienne Tedesco, Jin Zhang

Drug Metab Dispos· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antiviral Nucleotide Incorporation by Recombinant Human Mitochondrial RNA Polymerase Is Predictive of Increased In Vivo Mitochondrial Toxicity Risk.
Martijn Fenaux, Xiaodong Lin, Fumiaki Yokokawa, Zachary Sweeney, Oliver Saunders, Helen Gu

Antimicrob Agents Chemother· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disposition and metabolism of [(14)C] Sacubitril/Valsartan (formerly LCZ696) an angiotensin receptor neprilysin inhibitor, in healthy subjects.
Jimmy Flarakos, Yancy Du, Timothy Bedman, Qusai Al-Share, Pierre Jordaan, Helen Gu

Xenobiotica· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of Three Novel Ring Expansion Metabolites of KAE609, a New Spiroindolone Agent for the Treatment of Malaria, in Rats, Dogs, and Humans.
Su-Er W Huskey, Chun-qi Zhu, Melissa M Lin, Ry R Forseth, Helen Gu

Drug Metab Dispos· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physiologically based pharmacokinetic modeling for assessing the clinical drug-drug interaction of alisporivir.
Binfeng Xia, Avantika Barve, Tycho Heimbach, Tao Zhang, Helen Gu

Eur J Pharm Sci· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time-dependent inhibition and induction of human cytochrome P4503A4/5 by an oral IAP antagonist, LCL161, in vitro and in vivo in healthy subjects.
Shyeilla Dhuria, Heidi Einolf, James Mangold, Suman Sen, Helen Gu

J Clin Pharmacol· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of dengue virus RNA synthesis by an adenosine nucleoside.
Yen-Liang Chen, Zheng Yin, Jeyaraj Duraiswamy, Wouter Schul, Chin Chin Lim, Helen Gu

Antimicrob Agents Chemother· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Absorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans.
Handan He, Phi Tran, Hequn Yin, Harold Smith, Yannick Batard, Helen Gu

Drug Metab Dispos· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and metabolism of lumiracoxib in healthy male subjects.
James B Mangold, Helen Gu, Lolita C Rodriguez, Johanne Bonner, Janet Dickson

Drug Metab Dispos· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
N-alkyl urea hydroxamic acids as a new class of peptide deformylase inhibitors with antibacterial activity.
Corinne J Hackbarth, Dawn Z Chen, Jason G Lewis, Kirk Clark, James B Mangold, Helen Gu

Antimicrob Agents Chemother· September 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis